ProQR Therapeutics N.V. (PRQR) vs Entrada Therapeutics, Inc. (TRDA)

ProQR Therapeutics N.V. and Entrada Therapeutics, Inc. are both Biotechnology companies. ProQR Therapeutics N.V. and Entrada Therapeutics, Inc. are of similar size ($242.2M and $236.1M). ProQR Therapeutics N.V. grew revenue faster over the last twelve months: 19.7% against −94.1%. ProQR Therapeutics N.V. has the higher net margin (−228.7% vs −3,537.7%) and the higher return on invested capital (0.00% vs −1,060.2%). Across the 16 metrics below, ProQR Therapeutics N.V. leads on 11 and Entrada Therapeutics, Inc. on 5.

Valuation

Metric PRQR TRDA Biotechnology median
P/E n/m n/m 7.88
P/S 8.45 55.50 11.47
P/B 1.96 1.11 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2.60 7.91 10.73
Earnings yield (27.88%) (64.29%) (28.84%)
Free cash flow yield (31.63%) (51.66%) (23.03%)

Profitability

Metric PRQR TRDA Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (233.33%) (3,767.07%) 0.00%
Net margin (228.71%) (3,537.73%) 0.00%
Free cash flow margin (267.36%) (2,867.07%) 0.00%
Return on equity (58.29%) (54.09%) (57.72%)
Return on assets (31.53%) (44.35%) (49.22%)
Return on invested capital 0.00% (1,060.24%) 0.00%

Growth

Metric PRQR TRDA Biotechnology median
Revenue growth (TTM) 19.72% (94.10%) 5.64%
EPS growth (last fiscal year) (28.57%) (306.55%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PRQR TRDA Biotechnology median
Debt to equity 0.06 0.00 0.00
Current ratio 3.49 10.89 4.73
Net debt to EBITDA 2.15 1.88 0.96

Dividend

Metric PRQR TRDA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric PRQR TRDA Biotechnology median
Market cap 236.13m 242.19m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack